Anglikan: The only innovative drug project currently under research is ALK-N001.

Golden Ten Data on June 9, Anglikang issued a change announcement, the company's shares for 2 consecutive trading days closing price deviation of more than 20%, belongs to the abnormal fluctuation of stock trading. The company's current innovative drug project under development is only ALK-N001, which obtained the drug clinical trial approval notice in April 2025 and is still in the phase I clinical trial stage as of the disclosure date of this announcement. The R&D of innovative drugs has the characteristics of long cycle, large investment and high uncertainty, so investors should pay attention to investment risks.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)